The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

(2022) Aaron C. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY

Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy

(2022) Anubhab Mukherjee et al.   ACTA PHARMACOLOGICA SINICA

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers

(2022) Chao-Yu Liu et al.   Journal of the Chinese Medical Association

Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations

(2021) Hidetoshi Hayashi et al.   Clinical Lung Cancer

Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)

(2021) Liping Hu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Liposomes: Advancements and innovation in the manufacturing process

(2020) Sanket Shah et al.   ADVANCED DRUG DELIVERY REVIEWS

Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways

(2020) Zhen Liu et al.   BIOMEDICINE & PHARMACOTHERAPY

Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness

(2019) Michela Terlizzi et al.   PHARMACOLOGY & THERAPEUTICS

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line

(2019) Nele Van Der Steen et al.   BIOCHEMICAL PHARMACOLOGY

Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer

(2019) Priyanka Chowdhury et al.   BMC CANCER

Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update

(2019) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

(2018) Gonzalo Recondo et al.   Nature Reviews Clinical Oncology

The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer

(2018) Najwa El Kadi et al.   CANCER RESEARCH

Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways

(2017) Zhen Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Crizotinib resistance: implications for therapeutic strategies

(2016) I. Dagogo-Jack et al.   ANNALS OF ONCOLOGY

Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer

(2016) Masayoshi Miyawaki et al.   MOLECULAR CANCER RESEARCH

Activation of EGFR Bypass Signaling by TGF  Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells

(2015) T. Tani et al.   MOLECULAR CANCER THERAPEUTICS

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE